Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Surgery, Univer...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-07-01
|
| Series: | Psoriasis: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/long-term-efficacy-and-safety-of-guselkumab-for-moderate-to-severe-pso-peer-reviewed-fulltext-article-PTT |
| _version_ | 1811224901685608448 |
|---|---|
| author | Megna M Potestio L Fabbrocini G Ruggiero A |
| author_facet | Megna M Potestio L Fabbrocini G Ruggiero A |
| author_sort | Megna M |
| collection | DOAJ |
| description | Matteo Megna, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 081 7462457, Fax +39 081 7462442, Email angeloruggiero1993@libero.itIntroduction: Guselkumab safety and efficacy profiles in psoriasis have been showed by VOYAGE (1 and 2) trials. Although trial results have been already previously confirmed by real-life studies, long-term real-life data, and drug survival data about guselkumab are still poor.Patients and Methods: We performed a 3-year retrospective study, with the aim of assessing guselkumab efficacy and safety profile in the management of plaque psoriasis in a real-life setting.Results: Thirty-one patients completed the study. Both Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) statistically improved since week 16, and up to week 144 [PASI reduction from 16.4 ± 6.2 to 0.6 ± 0.9 (p < 0.0001) at week 144 while BSA from 33.2 ± 14.6 to 1.9 ± 1.4 (p < 0.0001)]. At week 12 PASI90 and PASI100 were achieved by 19 (61.3%) and 11 (35.4%) patients, respectively, as well as 24 (77.4%) and 18 (58.1%) subjects reached PASI 90 and PASI 100 at week 144. As regards the safety, no cases of injection site reaction, candida, serious AEs, malignancy, or major cardiovascular events were reported. Of note, mild AEs were collected with pharyngitis as the main one (7, 22.6%), followed by headache (5, 16.1%) and flu-like illness (5, 16.1%), all without requiring treatment discontinuation.Conclusion: Our experience confirmed the efficacy and safety of guselkumab in daily clinical practice up to 3 years, suggesting this drug as an effective treatment option in psoriasis long-term management.Keywords: psoriasis, guselkumab, IL-23, anti-IL-23, real life, biologic, IL-23, IL-17A |
| first_indexed | 2024-04-12T08:57:45Z |
| format | Article |
| id | doaj.art-f1c571f516a049f9accd9d267556801e |
| institution | Directory Open Access Journal |
| issn | 2230-326X |
| language | English |
| last_indexed | 2024-04-12T08:57:45Z |
| publishDate | 2022-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Psoriasis: Targets and Therapy |
| spelling | doaj.art-f1c571f516a049f9accd9d267556801e2022-12-22T03:39:21ZengDove Medical PressPsoriasis: Targets and Therapy2230-326X2022-07-01Volume 1220521276564Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective StudyMegna MPotestio LFabbrocini GRuggiero AMatteo Megna, Luca Potestio, Gabriella Fabbrocini, Angelo Ruggiero Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 081 7462457, Fax +39 081 7462442, Email angeloruggiero1993@libero.itIntroduction: Guselkumab safety and efficacy profiles in psoriasis have been showed by VOYAGE (1 and 2) trials. Although trial results have been already previously confirmed by real-life studies, long-term real-life data, and drug survival data about guselkumab are still poor.Patients and Methods: We performed a 3-year retrospective study, with the aim of assessing guselkumab efficacy and safety profile in the management of plaque psoriasis in a real-life setting.Results: Thirty-one patients completed the study. Both Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) statistically improved since week 16, and up to week 144 [PASI reduction from 16.4 ± 6.2 to 0.6 ± 0.9 (p < 0.0001) at week 144 while BSA from 33.2 ± 14.6 to 1.9 ± 1.4 (p < 0.0001)]. At week 12 PASI90 and PASI100 were achieved by 19 (61.3%) and 11 (35.4%) patients, respectively, as well as 24 (77.4%) and 18 (58.1%) subjects reached PASI 90 and PASI 100 at week 144. As regards the safety, no cases of injection site reaction, candida, serious AEs, malignancy, or major cardiovascular events were reported. Of note, mild AEs were collected with pharyngitis as the main one (7, 22.6%), followed by headache (5, 16.1%) and flu-like illness (5, 16.1%), all without requiring treatment discontinuation.Conclusion: Our experience confirmed the efficacy and safety of guselkumab in daily clinical practice up to 3 years, suggesting this drug as an effective treatment option in psoriasis long-term management.Keywords: psoriasis, guselkumab, IL-23, anti-IL-23, real life, biologic, IL-23, IL-17Ahttps://www.dovepress.com/long-term-efficacy-and-safety-of-guselkumab-for-moderate-to-severe-pso-peer-reviewed-fulltext-article-PTTpsoriasisguselkumabil-23anti-il-23real lifebiologicil-23il-17a. |
| spellingShingle | Megna M Potestio L Fabbrocini G Ruggiero A Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study Psoriasis: Targets and Therapy psoriasis guselkumab il-23 anti-il-23 real life biologic il-23 il-17a. |
| title | Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study |
| title_full | Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study |
| title_fullStr | Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study |
| title_full_unstemmed | Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study |
| title_short | Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study |
| title_sort | long term efficacy and safety of guselkumab for moderate to severe psoriasis a 3 year real life retrospective study |
| topic | psoriasis guselkumab il-23 anti-il-23 real life biologic il-23 il-17a. |
| url | https://www.dovepress.com/long-term-efficacy-and-safety-of-guselkumab-for-moderate-to-severe-pso-peer-reviewed-fulltext-article-PTT |
| work_keys_str_mv | AT megnam longtermefficacyandsafetyofguselkumabformoderatetoseverepsoriasisa3yearrealliferetrospectivestudy AT potestiol longtermefficacyandsafetyofguselkumabformoderatetoseverepsoriasisa3yearrealliferetrospectivestudy AT fabbrocinig longtermefficacyandsafetyofguselkumabformoderatetoseverepsoriasisa3yearrealliferetrospectivestudy AT ruggieroa longtermefficacyandsafetyofguselkumabformoderatetoseverepsoriasisa3yearrealliferetrospectivestudy |